We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+46.74%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$3.57B
AUM Growth
+$1.21B
Cap. Flow
+$318M
Cap. Flow %
8.9%
Top 10 Hldgs %
45.04%
Holding
142
New
39
Increased
22
Reduced
59
Closed
10

Top Buys

Rank Stock Value
1
GDS icon
GDS Holdings
GDS
+$68.1M
2
GBIO
Generation Bio
GBIO
+$62.7M
3
RPRX icon
Royalty Pharma
RPRX
+$37.1M
4
ONC
BeOne Medicines Ltd
ONC
+$32.6M
5
NG icon
NovaGold Resources
NG
+$26.3M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$137M
2
AVTR icon
Avantor
AVTR
+$40.7M
3
PYPL icon
PayPal
PYPL
+$33.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$27M
5
Z icon
Zillow
Z
+$20.7M

Sector Composition

Rank Sector Weight
1 Healthcare 61.98%
2 Consumer Discretionary 13.38%
3 Technology 3.16%
4 Financials 1.15%
5 Communication Services 0.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRVL
101
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$5.51M 0.15%
370,000
+170,000
+85% +$2.62M
TCRR
102
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$5.38M 0.15%
350,000
-50,000
-13% -$577K
SLDB icon
103
Solid Biosciences
SLDB
$795M
$5.27M 0.15%
120,000
– –
SYRS
104
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$5.22M 0.15%
49,000
-1,614
-3% -$145K
ORIC icon
105
Oric Pharmaceuticals
ORIC
$1.16B
$5.06M 0.14%
+150,000
New +$4.79M
NTLA icon
106
Intellia Therapeutics
NTLA
$1.49B
$5.02M 0.14%
+239,000
New +$4.06M
AXLA
107
DELISTED
Axcella Health Inc. Common Stock
AXLA
$4.98M 0.14%
36,000
+12,000
+50% +$1.47M
RNAM
108
DELISTED
Avidity Biosciences
RNAM
$4.95M 0.14%
+175,000
New +$5.05M
ALEC icon
109
Alector
ALEC
$171M
$4.89M 0.14%
200,000
-50,000
-20% -$1.38M
ZNTL icon
110
Zentalis Pharmaceuticals
ZNTL
$325M
$4.42M 0.12%
+92,000
New +$3.53M
YI
111
111 Inc
YI
$33.4M
$4.13M 0.12%
65,000
– –
PRTA icon
112
Prothena Corp
PRTA
$443M
$3.87M 0.11%
370,000
+70,000
+23% +$778K
KLDO
113
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$3.72M 0.1%
500,500
– –
IDYA icon
114
IDEAYA Biosciences
IDYA
$3.44B
$3.4M 0.1%
+239,304
New +$1.89M
DNTH icon
115
Dianthus Therapeutics
DNTH
$5.57B
$3.38M 0.09%
+28,125
New +$3.96M
CLVS
116
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$3.38M 0.09%
500,000
– –
EVLO
117
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$3.27M 0.09%
+33,333
New +$2.92M
LITS
118
Lite Strategy Inc
LITS
$32.8M
$2.95M 0.08%
+35,700
New +$2.16M
NERV icon
119
Minerva Neurosciences
NERV
$196M
$2.89M 0.08%
100,000
-25,000
-20% -$1.47M
CYRX icon
120
CryoPort
CYRX
$751M
$2.69M 0.08%
+89,000
New +$1.98M
PTGX icon
121
Protagonist Therapeutics
PTGX
$8.84B
$2.47M 0.07%
+140,000
New +$1.76M
ORTX
122
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$2.22M 0.06%
37,000
-3,000
-8% -$275K
KDNY
123
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.19M 0.06%
190,000
-10,000
-5% -$138K
ACET icon
124
Adicet Bio
ACET
$76.6M
$2.05M 0.06%
+8,509
New +$1.67M
XLE icon
125
CALL
State Street Energy Select Sector SPDR ETF
XLE
$39.2B
$1.89M 0.05%
+100,000
New +$1.86M
2 3 4
5
6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2020 Portfolio in Review

As of Q2 2020, Artal Group held 142 positions worth $3.57B, up 51% from $2.37B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Artal Group deployed $318M of net new capital in Q2 2020, opening 39 new positions and adding to 22 existing holdings. Its largest new stake was GDS Holdings: 1,100,000 shares worth $87.6M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 69% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Moderna, an estimated $137M trimmed.

  • Artal Group's largest Q2 2020 buy was GDS Holdings: 1,100,000 shares worth $87.6M.
  • Artal Group added most to BeOne Medicines Ltd in Q2 2020, an estimated $32.6M increase.
  • Artal Group's biggest Q2 2020 reduction was Moderna, cutting an estimated $137M.
  • Artal Group fully exited Arrowhead Research in Q2 2020, selling an estimated $17.3M.
  • Artal Group's ten largest holdings make up 45% of its $3.57B portfolio in Q2 2020.
  • Artal Group opened 39 new positions and closed 10 in Q2 2020.
  • Artal Group's portfolio value rose 51% quarter-over-quarter to $3.57B.

Based on Artal Group's 13F filing for Q2 2020, filed 14 Aug 2020.